Viking Therapeutics Jumps 35.7% on Weight-Loss Drug Trial Data

Viking Therapeutics closed up 35.67% at $40.85 after VK2735 trial patients lost 16-19% of body weight. The real draw: less frequent dosing than current obesity drugs.